Introduction
Calcium channel blockers (CCBs), which target voltage-dependent Ca channels, are widely used in the field of hypertension therapy and rank second in the pharmaceutical market for hypertension treatment. Indeed, CCBs are believed to have less serious adverse effects than other antihypertensive drugs and are recognized as reliable drugs in terms of lowering blood pressure. A growing body of evidence, however, points to a problem associated with kidney function. Conventional CCBs, including nifedipine, diltiazem and amlodipine, elicit marked increases in the glomerular filtration rate and renal blood flow 1 -3 by dilating afferent arterioles preferentially, 4 -8 whereby glomerular hypertension and subsequent renal injury are expected to ensue unless systemic blood pressure is sufficiently controlled. [9] [10] [11] [12] Voltage-dependent Ca channels are widely distributed throughout the body and play a critical role in the maintenance of vascular tone. Ca channels are classified into several subtypes, including L-type, T-type, N-type, P/Qtype and R-type Ca channels based on their electrophysiological properties; 1 3 among these subtypes, the L-type Ca channel has been most extensively investigated for elucidation of its function. The blockade of L-type Ca channels dilates the systemic vasculature and substan-tially reduces blood pressure. In the renal microvasculature, however, the vasodilator response to L-type CCBs is observed only in preglomerular microvessels (e.g., afferent arterioles), whereas efferent arterioles are refractory to the dilator action of these agents. [4] [5] [6] [7] [8] The renal microvascular response thus supports speculation that glomerular hypertension may develop following the administration of these agents.
In contrast, T-type Ca channels have been identified as an important molecular target in various organs, and they function as a part of physiological and/or pathophysiological activities. 1 4 In the cardiac sinus node, T-type Ca channels participate in the generation of the pacemaker potential. 1 5 In the kidney, several Ca channel subtypes are reported to be present, including L-type, T-type, N-type and P/Q-type Ca channels. 1 6, 1 7 Recently, much interest has been focused on the role of T-type Ca channels in the kidney. It has been demonstrated that the blockade of T-type Ca channels exerts a beneficial action on kidney function in chronic kidney disease (CKD), including reduction in proteinuria 1 8-2 2 and improvement in kidney survival. 2 3 Collectively, the role of Ca channels may differ depending on the subtype expression within the kidney, and the specific blockade of Ca channel subtypes would be anticipated to exert a salutary action on the renal microvasculature.
In this article, we review the role of Ca channel subtypes in renal physiology. Furthermore, the effects of the blockade of these Ca channels on CKD are also surveyed.
Ca Channel Subtypes
Voltage-dependent Ca channels are classified into L-, P/Q-, N-, R-and T-type subtypes based on their pharmacological and electrophysiological properties; they are made up of heteromeric multisubunits, including α1, α2, β, δ and γ (skeletal muscle). 1 3 Among these, the α1 subunit possesses the main characteristics of the Ca channel, such as the ion-conducting pore, ion selectivity and voltage sensitivity, and is encoded by the CACNA1 gene family, which consists of 10 genes (Fig. 1) . In the kidney, a number of Ca channels with various α1 subunits, including Ca V 2.1 (α1A), Ca V 1.2 (α1C), Ca V 1.3 (α1D), Ca V 3.1 (α1G) and Ca V 3.2 (α1H), are expressed and function as L-type (Ca V 1.2, Ca V 1.3), T-type (Ca V 3.1, Ca V 3.2) and P/Q-type (Ca V 2.1) Ca channels; 1 3 precise or organized electrophysiological analyses, however, have not been conducted because the kidney contains divergent cell populations. Furthermore, the kidney is supplied with numerous nerve endings that possess N-type (α1B) Ca channels. Interestingly, P-(Ca V 2.1a) and Q-type (Ca V 2.1b) Ca channel subunits are splice variants of a single gene (i.e., CACNA1A) and are expressed in the afferent arteriole. 1 6 Although splice variants have been demonstrated in neuronal and cardiac cells 2 4 as well as in vascular smooth muscle cells from atherosclerotic tissues, 2 5 whether these variants affect the renal function remains undetermined.
Characterization of Renal Microvessels
Afferent and efferent arterioles exist adjoining the glomerulus; they adjust their vascular tone in response to various vasoactive stimuli. The fact that glomerular filtration exhibits divergent changes depending on the vasoactive stimuli applied implies that the responsiveness of afferent and efferent arterioles to these stimuli differs. For example, atrial natriuretic peptide causes afferent arteriolar dilation and efferent arteriolar constriction. 2 6, 2 7 Furthermore, elevated renal perfusion pressure 2 8 , endothelin 2 9 and high K levels 3 0 elicit predominant constriction of the afferent arteriole.
It has been demonstrated that voltage-dependent Ca channels functionally prevail in the afferent arteriole.
4, 7, 3 0-3 3 High K-induced membrane depolarization selectively constricts the afferent arteriole, whereas the efferent arteriole is relatively insensitive to such depolarization. 3 3 5 and verapamil, 4, 7 cause a greater increase in glomerular filtration rate than that in renal plasma flow, resulting in an elevated filtration fraction. These observations suggest predominant action on the afferent arteriole. However, in the in vivo setting, systemic blood pressure is decreased, which may confound the effect of CCBs on renal arterioles. To eliminate the pressure-induced changes in vascular tone, Loutzenhiser, et al. 5, 3 6-3 8 used the isolated perfused rat normal kidney model. This model provides constant renal perfusion pressure, whereby the myogenic tone of renal microvessels is unaltered. In a series of the experiments, Loutzenhiser, et al. found that under angiotensin II-or norepinephrine-induced vasoconstrictor tone, CCBs including nifedipine, nisoldipine, diltiazem and amlodipine caused greater increases in glomerular filtration rate than those in renal plasma flow, resulting in exaggerated increases in filtration fraction. 5, 3 6-3 8 Thus, these observations again support the finding that CCBs act predominantly on the renal preglomerular vessels.
Recent advances in laboratory techniques have facilitated more detailed direct observation of the renal microcirculation. 2 7-3 0, 3 9-4 5 Casellas and Navar 4 3 developed an in vitro technique that allows direct visualization of the juxtamedullary nephron circulation. In their experiments, both verapamil and diltiazem potently inhibited afferent arteriolar vasoconstriction, whereas efferent arterioles were relatively refractory to the vasodilator action of these agents. 46 Similarly, Ito, et al. 41, 42 developed the isolated renal cortical microvessel model and found that nifedipine predominantly dilated the afferent arteriole. 4 7 Loutzenhiser and Epstein developed a model of the isolated perfused hydronephrotic kidney that facilitated direct observation of the renal microvasculature under defined in vitro conditions. 2 7-3 0 Using this model, we demonstrated that both dihydropyridine-class (e.g., nifedipine, nicardipine and amlodipine) and benzothiazepine-class (e.g., diltiazem) CCBs reversed the angiotensin II-induced constriction of the afferent arteriole, whereas the efferent arteriole was refractory to the vasodilator action of these antagonists. 4 8, 4 9 Furthermore, using intravital pencil-lens CCD camera videomicroscopy, we observed that nifedipine caused predominant dilation of the afferent arteriole in the canine kidney ( Fig. 2A) . 5 0 Of note, we also have shown that nifedipine elevates the filtration fraction (i.e., glomerular filtration rate/renal plasma flow) in dogs 5 0 (Fig. 2B ). Since this parameter nearly parallels the glomerular capillary pressure, our findings suggest a potential risk for the development of glomerular hypertension as a result of nifedipine administration.
The preferential afferent arteriolar action of CCBs suggests the predominant distribution of L-type Ca channels in this vessel (Fig. 3) . Indeed, Hansen, et al. 1 7 have demonstrated that mRNA encoding Ca V 1.2 (α1C) L-type Ca channel subunits is expressed in afferent arterioles from rabbit cortical preglomerular arterioles. In contrast, this subunit was not found in cortical efferent arterioles, although it was present in juxtamedullary efferent arterioles. Similarly, Ono, et al. [personal communication] have recently demonstrated that Ca V 1.2 is prevalent in the rat afferent arteriole, whereas the efferent arteriole lacks this subunit. These observations thus endorse the functional evidence indicating preferential activity of L-type Ca channels in the afferent, but not in the efferent, arteriole.
In summary, it is reasonable to conclude that voltagedependent Ca channels predominate in the afferent arteriole; in contrast, these channels are sparse or functionally silent in the efferent arteriole.
Role of T-type and N-type Ca Channels in Renal Microvessels
Unlike the conventional types of CCBs, novel CCBs developed in Japan (e.g., manidipine and efonidipine) are reported to dilate both afferent and efferent arterioles.
8, 1 0 Using microdissected renal arterioles, Arima, et al. 4 7 reported that manidipine caused efferent as well as afferent arteriolar dilation. Furthermore, Takabatake, et al. 5 1 reported that in a rat micropuncture study, efonidipine reduced pre-and postglomerular capillary resistance. Finally, we demonstrated that several CCBs, including manidipine, nilvadipine, benidipine and efonidipine, cause substantial dilation of efferent arterioles in the isolated perfused rat hydronephrotic kidney. 4 8, 5 2, 5 3 Since traditional CCBs act on L-type voltage-dependent Ca channels, and these channels are predominant in the afferent arteriole, 3 0, 5 3 the effects on the efferent arteriole by these CCBs are most likely attributed to additional actions of these CCBs, not due to the class effects of these agents.
Recently, a pharmacological study has demonstrated that efonidipine possesses blocking activity toward T-type, as well as L-type, voltage-dependent Ca channels. 54 T-type Ca channels are distributed substantially in several parts of the microvasculature, including mesenteric and cremaster arterioles, and the blockade of these channels by selective T-type CCBs, e.g., mibefradil, inhibits the vasoconstriction of these arterioles. In the renal microvasculature, Hansen, et al. 1 7 demonstrated that T-type Ca channels are prevalent in juxtamedullary efferent arterioles, as well as in afferent arterioles of superficial and juxtamedullary nephrons. Furthermore, using in situ hybridization, Ono, et al. recently identified the Ca V 3.1 subunit (an α1 subunit of T-type Ca channels) in superficial efferent as well as in afferent arterioles [personal communication] . Similarly, using the micropuncture technique, Nakamura, et al. 5 5 found that mibefradil decreased both afferent and efferent arteriolar resistance in kidneys from spontaneously hypertensive rat (SHR) kidneys. Recently, Ozawa, et al. 5 6 directly visualized efferent arteriolar dilation by some CCBs that possess blocking activity toward T-type Ca channels. Both mibefradil and nickel chloride potently reverse the angiotensin II-induced constriction of efferent arterioles in the isolated perfused hydronephrotic rat kidney model. Furthermore, the intravital pencil-type CCD camera tech- nique revealed that efonidipine and mibefradil provoke efferent as well as afferent arteriolar dilation in dog kidneys in vivo 5 0 (Fig. 2A) . Collectively, these novel findings strongly suggest a critical role for T-type Ca channels in mediating the efferent arteriolar tone.
N-type Ca channels are present at sympathetic nerve terminals that are distributed along afferent and efferent arterioles. It has been reported that cilnidipine, an N-type CCB, reduced both afferent and efferent arteriolar resistance in a renal micropuncture study of nitro-Larginine methylester-treated SHR 5 7 and dilated both arterioles in the in vivo hydronephrotic kidney. 5 8 Similarly, using an intravital CCD camera, we found that cilnidipine causes substantial vasodilation of efferent, as well as afferent, arterioles in the canine kidney in vivo ( Fig. 2A) . This class of CCB is characterized by a unique pharmacological action, i.e., inhibitory action on norepinephrine secretion 5 9, 6 0 and neurally stimulated renal vasoconstriction. 6 1 It is noteworthy that, in the in vitro isolated perfused hydronephrotic kidney, cilnidipine elicits predominant action in the afferent arteriole. 6 2 It was inferred, therefore, that the integrity of the sympathetic nerve is required for the full activity of N-type CCBs.
The vasodilator action of T-type and N-type CCBs on renal microvessels favors reduced glomerular capillary pressure. Indeed, we have shown that both T-type (efonidipine and mibefradil) and N-type CCBs (cilnidipine) reduce or tend to decrease the filtration fraction, an observation contrasting the effects of nifedipine (Fig. 2B) . 50 
Role of CCBs in the Progression of Renal Injury
The glomerular hemodynamic effects of L-type CCBs suggest that these CCBs fail to correct glomerular hypertension in certain experimental conditions. The overall effect of L-type CCBs on glomerular hemodynamics is determined by the balance between the reduction in afferent arteriolar resistance and the fall in systemic blood pressure, and the changes in these two factors may vary depending on the experimental settings, the magnitude of depressor activity, and the types of CCBs used. For example, verapamil is reported to reduce proteinuria and protect against renal injury in remnant kidney models. 6 3, 6 4 In contrast, there have been several reports suggesting deleterious effects of dihydropyridine-class CCBs in renal diseases.
9-1 2, 6 5-6 7 Wenzel, et al. 6 6 demonstrated that nitrendipine actually increased proteinuria and glomerulosclerosis in a two-kidney, one-clip model of hypertension.
In contrast, CCBs that act on both L-type and T-type Ca channels and dilate afferent and efferent arterioles may alleviate glomerular hypertension and could exert salutary actions on the progression of renal injury. Shudo, et al. 1 8, 6 8, 6 9 reported that efonidipine acutely decreased proteinuria in spontaneously hypertensive rats, whereas systemic blood pressure was only partially reduced. Additionally, mibefradil potently prevents the development of renal injury in SHR 5 5 and DOCA hypertensive rats.
2 0 Likewise, cilnidipine, an L-type and N-type CCB, has been reported to suppress the elevation in blood pressure and blunt the progression of renal injury in Dahl salt-sensitive rats 7 0 and to ameliorate glomerular injury and proteinuria in Dahl rats fed on a high-sucrose diet. 71 Our previous studies demonstrated that 8-week-treatment with CCBs including nifedipine and efonidipine showed contrasting effects for these antagonists. 5 2 Despite the same reduction in systemic blood pressure, efonidipine markedly prevented an increase in proteinuria, whereas nifedipine did not prevent an increase in proteinuria in subtotally nephrectomized SHR, a model of CKD with hypertension. 72 Furthermore, the histopathological changes and serum creatinine levels were also ameliorated by efonidipine but not by nifedipine. Of note, efonidipine reduces proteinuria to the same level as enalapril, and both drugs cause afferent and efferent arteriolar dilation. Thus, the renal protective effect of efonidipine may be attributed, at least in part, to the glomerular hemodynamic action of this agent, since efonidipine is anticipated to reduce glomerular capillary pressure in the same way that enalapril does.
Mechanisms for T-type CCB-induced Renal Protection
In addition to hemodynamic factors, multiple mechanisms appear to contribute to the ability of T-type CCBs to protect the kidney. It has been reported that CCBs suppress mesangial cell proliferation by inhibiting activator protein-1 (AP-1) 7 3 and that CCBs modulate gene transcriptions involved in proinflammatory changes (interleukin 1β and granulocyte/monocyte colony stimulating factors). 7 4 Efonidipine, a T-type Ca antagonist, has been shown to suppress the phorbol myristate acetate (PMA)-induced activation of nuclear factor kappa B (NF-κB) in cultured human mesangial cells. 7 5 Furthermore, CCBs could act as free radical scavengers. 76 Rossier, et al. 7 7 found that aldosterone release provoked by angiotensin II and KCl was inhibited by mibefradil but not by nicardipine, suggesting an important contribution of T-type Ca channels to aldosterone release. Similarly, Somekawa, et al. 7 8 recently demonstrated that efonidipine downregulates the expression of aldosterone synthetase, CYP11B2, in rat adrenal cells. Indeed, plasma aldosterone levels are reported to be lower in patients with hypertension 7 9 or chronic glomerulonephritis treated with efonidipine rather than with amlodipine.
8 0 Since aldosterone is reported to promote renal injury, 8 1 the blockade of aldosterone release would be anticipated to exert salutary action on the progression of renal injury.
We have recently shown that Rho kinase activation participates in the progression of renal injury in subtotal nephrectomized rats, a model of chronic renal failure. 8 2 Conversely, the inhibition of Rho kinase should therefore confer benefit in the treatment of renal disease 8 3-8 5 in addition to its hypotensive action. 8 6 Of interest, our recent study demonstrated that T-type CCBs prevent renal Rho kinase activation induced by subtotal nephrectomy and alleviate the progression of kidney disease (Fig.  4) . 8 7 Furthermore, the expression of T-type Ca channels is upregulated in kidneys from rats with chronic kidney disease. 8 7 Since Rho kinase is known to elicit the inflammatory process as well as the enhancement of vascular tone, 8 8 the blockade of T-type Ca channels is expected to act as a tool for the prevention of CKD.
In summary, T-type Ca channels play an important role in the development of chronic kidney disease, which action is mediated by multifaceted pathways, including hemodynamic, hormonal and inflammatory factors.
Clinical Aspects of the Role of CCBs
The divergent action of L-type and T-type CCBs on renal microcirculation and kidney injury in animal models may be extrapolated to human CKD. Previous clinical trials, including ALLHAT (Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial) 8 9 and INSIGHT (Intervention as a Goal in Hypertension Treatment), 9 0 showed equivocal effects of L-type CCBs (amlodipine and nifedipine) on the progression of CKD, compared with ACE inhibitors or diuretics ( Table 1) . In contrast, AASK (African American Study of Kidney Disease and Hypertension) 9 1 demonstrated that the amlodipine-treated group manifested an elevation in glomerular filtration rate (GFR) at 3 months but exhibited a greater reduction in GFR than the ACE inhibitor-treated group in African American patients without diabetes mellitus (non-DM) with CKD. Furthermore, the addition of felodipine to ACE inhibitor therapy conferred no additive benefit in non-DM patients with CKD (REIN-2; Ramipril Efficacy in Nephropathy trial-2).
9 2 Additionally, IDNT (Irbesartan Diabetic Nephropathy Trial), in which the effect of and irbesartan on the progression of CKD was evaluated, revealed that amlodipine [an angiotensin receptor blocker (ARB)] potently prevented the progression of CKD, whereas amlodipine failed to offer renal protection in type 2 diabetic patients with CKD. 9 3 Similarly, the GUARD (Gauging Albuminuria Reduction with Lotrel in Diabetic Patients with Hypertension) trial showed that the reduction in albuminuria was less in the amlodipine-treated group than in the diuretics-treated group. 9 4 Head-to-head comparison of amlodipine vs. valsartan also unveiled an increase in albuminuria in Japanese type 2 DM patients treated with amlodipine (SMART; Shiga Microalbuminuria Reduction Trial). 9 5 In concert, these observations suggest reduced or no protective action of the L-type CCB in the progression of CKD.
One caveat is that the adequate control of blood pressure would be anticipated to alleviate the progression of CKD. In the sub-analysis of IDNT, the relative risk for the development of end-stage renal disease was reported to be lower in patients with systolic blood pressure below 121 mmHg, and the risk in the amlodipine-treated group tended to parallel the levels of systolic blood pressure. 9 3 Furthermore, in the NICE Combi (Nifedipine and Candesartan Combination) study, in which the effects of the maximal dose of candesartan and combination therapy with candesartan and controlled-release nifedipine on microalbuminuria were compared, the combination treatment group manifested significantly reduced albu- Effects of Ca channel blockers on the expression of α-smooth muscle action (SMA) and interstitial fibrosis in kidneys from SHR-Nx. R(-) indicates an R(-)-enantiomer of efonidipine that selectively blocks T-type Ca channels but has no effect on L-type Ca channels. Data adopted with modification from Sugano N, et al. minuria with greater reductions in systemic blood pressure. 9 6 Accordingly, these observations lend support to the formulation that strict blood pressure control offers renal protection that does not depend on the type of antihypertensive agent used.
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In contrast, a growing body of clinical evidence has shown that CCBs with blocking activity toward T-type Ca channels provide salutary action in protection against renal injury ( Table 2) . We previously demonstrated that efonidipine was as potent as ACE inhibitors in reducing proteinuria. 2 1 Furthermore, efonidipine significantly reduced proteinuria even in a subset of patients in which mean blood pressures failed to decrease below 100 mmHg. Ishimitsu, et al. 8 0 also reported that switching from amlodipine to efonidipine caused a significant decrease in proteinuria in patients with chronic glomerulonephritis. Finally, comparison of azelnidipine (an L/Ttype CCB), Table 3 with amlodipine or nifedipine (Ltype CCBs) showed greater reductions in proteinuria by azelnidipine in patients with CKD 9 7 and DM, 9 8 respectively.
Cilnidipine is a representative N-type CCB( Table 3 ) and dilates both afferent and efferent arterioles through the inhibition of N-type Ca channels in nerve terminals innervating renal afferent and efferent arterioles. It has been reported that cilnidipine exerts antiproteinuric action when administered in patients with essential hypertension. 9 9 Recently, Fujita, et al. 1 0 0 demonstrated that add-on therapy with cilnidipine reduces proteinuria more potently than that with amlodipine in CKD patients treated with renin-angiotensin blocking agents (CART-ER study, Table 2 ). They suggest that the beneficial action of cilnidipine on proteinuria is mediated by the inhibition of sympathetic nerve activity and the resultant amelioration of glomerular hypertension. Of note, in a subset of the DM nephropathy group, they failed to show a significant decrease in proteinuria with cilnidipine. Since the salutary action of cilnidipine on proteinuria appears to be attributed to the blockade of N-type Ca channels, it is reasonable to speculate that the failure to alleviate proteinuria can be ascribed to the impaired integrity of sympathetic nerve terminals in DM. In contrast, Abe, et al. 1 0 1 recently demonstrated that during treatment with ARB, benidipine, but not amlodipine, potently reduces proteinuria in DM as well as in non-DM patients. Based on the pharmacological properties of benidipine (i.e., blocking action on L/T/N-type Ca channels), this study underscores a critical role of T-type Ca channel blockade not only in non-DM but also in DM patients.
Very recently, Omae, et al. 2 3 evaluated the long-term effects of CCBs with different Ca channel subtype activities on the development of end-stage renal disease in 107 non-DM CKD patients ( Table 2) . This prospective study used L-type CCBs (nifedipine, amlodipine, nicardipine and nitrendipine), L/T-type CCBs (benidipine, barnidipine, manidipine, nilvadipine and efonidipine, Table 3 ) and non-dihydropyridines (diltiazem and verapamil) and found that the use of L-type CCBs was associated with an increase in proteinuria. Furthermore, the use of L/T-type CCBs was associated with favorable outcomes, as assessed by the changes in eGFR and the renal survival rate. In summary, the results obtained from various clinical trials demonstrate that the effects of CCBs with L-type Ca channel specific blocking activity on renal outcomes vary depending on several factors, including underlying renal disease, the blood pressure achieved and the duration of the study. In contrast, CCBs with L/T-type blocking activity consistently offer favorable action on the development of CKD. Although the role of N-type Ca channel blockade in CKD appears intriguing, its actual effect may depend on the integrity of the underlying sympathetic nervous system.
Concluding Remarks
Pharmacological characterization of Ca channel subtypes and their blockers allows understanding of the role of these channels in the kidney. It is now established that the blockade of T-type or N-type Ca channels exerts renal protective action by abrogating glomerular hypertension through vasodilator action on both afferent and efferent arterioles. Additionally, T-type CCBs may provide beneficial action through multiple non-hemodynamic mechanisms that act to suppress inflammatory processes and the renin-angiotensin-aldosterone system. Such multifaceted action of T-type CCBs serves to protect against renal injury, and their use is anticipated to increase in the treatment of hypertension with CKD. Although these subclasses of CCB are clinically available only in Japan and South Korea, a growing body of evidence regarding their efficacy should facilitate the spread of knowledge on these novel types of CCBs. 
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